FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see the first data from FG001 study guiding cancer surgery in patients with head & neck cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague. The presentation contains a patient case. The poster “Optical-Guided Surgery in Patients .
FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field of precision cancer surgery, is pleased to announce the successful completion of patient enrollment and treatment in the phase llb trial with FG001 in patients with aggressive brain cancer. This means the trial is on track to read out .
Trial investigates the effect of FG001 in guiding surgery of patients with aggressive brain cancerThe multi-center trial compares FG001 to 5-ALA and white lightTopline results anticipated to be.
Copenhagen, Denmark, 6 November 2022 - FluoGuide A/S is pleased to announce that FG001 lights up in 5 out of 7 patients in an interim evaluation in the ongoing phase IIa trial in non-small cell lung. | November 6, 2022